ALISON FENNEY PROMOTED TO EXECUTIVE DIRECTOR, NEUROTECHNOLOGY INDUSTRY ORGANIZATION
San Francisco, CA (September 8, 2016) - The Neurotechnology Industry Organization (NIO) is marking its 10th anniversary with the addition of a new Executive Director, Alison Fenney, PhD, MBA, to oversee the next decade of growth and development. Alison joined NIO in 2015 as Director of Industry Alliances to expand the global membership and support the ongoing activities of the organization.
"Alison comes to NIO with a wealth of knowledge and connections across the spectrum of neurotechnology, from research to commercialization. Her unique background and experience position her perfectly to represent our diverse membership globally," said Zack Lynch, NIO Founder and Chairman. Mr. Lynch is now a General Partner at JAZZ Venture Partners, a venture capital firm he co-founded to invest in experiential technology to improve human performance.
Prior to joining NIO, Alison was Manager of Industry Relations at the Ontario Brain Institute (OBI) in Canada, where she developed and launched several innovative funding programs for seed stage and product development investments. She worked with local and federal governments, as well as, private enterprises to raise capital for over 25 new ventures, advocating on behalf of academic researchers and young entrepreneurs developing cutting edge neurotech products.
Before her work at OBI, Alison worked in equity research at Bloom Burton & Co, a boutique life science investment bank in Toronto, Canada. She also served on the board of AGE Inc. a social venture developing educational tools for dementia care. Alison maintains an advisory role with the Alzheimer Society HHNB, where she has been a volunteer since 2008.
"I am excited to step into this leadership role, having spent a very productive year on staff, and several years as part of the membership. I have the utmost respect for the work Zack and the team have done uniting the neurotechnology community across drugs, devices, diagnostics, IT and software. I look forward to growing the membership and advancing innovative policy to support the commercial neuroscience ecosystem globally," shared Alison.
Alison has a PhD in Neuroscience and an MBA from McMaster University, she also holds a Masters in Neurokinetics from the University of Quebec at Montreal, and Bachelor of Kinesiology (honors) from Brock University.
The neurotechnology sector has seen important increases in investment over the last decade, however, there remains significant unmet need across the majority of CNS diseases and disorders. The Neurotechnology Industry Organization, established in 2006, is the first and only trade organization representing commercial neuroscience globally.
About NIO
Since 2006, over 120 neuroscience organizations have joined the Neurotechnology Industry Organization in our mission to accelerate neurotechnology research, development and commercialization, including neuroscience companies, brain research institutes, and patient advocacy groups across the spectrum of neurological disease, psychiatric illnesses and nervous system injuries. NIO's programs have the following goals: advocate the industry's position to regulators and elected officials; inform the media about industry's progress and contributions to quality of life; provide industry events and business development services to the industry; foster leadership positions that drive innovation forward.
Contact:
Alison Fenney
Executive Director, NIO
Alison@neurotechindustry.org
"Alison comes to NIO with a wealth of knowledge and connections across the spectrum of neurotechnology, from research to commercialization. Her unique background and experience position her perfectly to represent our diverse membership globally," said Zack Lynch, NIO Founder and Chairman. Mr. Lynch is now a General Partner at JAZZ Venture Partners, a venture capital firm he co-founded to invest in experiential technology to improve human performance.
Prior to joining NIO, Alison was Manager of Industry Relations at the Ontario Brain Institute (OBI) in Canada, where she developed and launched several innovative funding programs for seed stage and product development investments. She worked with local and federal governments, as well as, private enterprises to raise capital for over 25 new ventures, advocating on behalf of academic researchers and young entrepreneurs developing cutting edge neurotech products.
Before her work at OBI, Alison worked in equity research at Bloom Burton & Co, a boutique life science investment bank in Toronto, Canada. She also served on the board of AGE Inc. a social venture developing educational tools for dementia care. Alison maintains an advisory role with the Alzheimer Society HHNB, where she has been a volunteer since 2008.
"I am excited to step into this leadership role, having spent a very productive year on staff, and several years as part of the membership. I have the utmost respect for the work Zack and the team have done uniting the neurotechnology community across drugs, devices, diagnostics, IT and software. I look forward to growing the membership and advancing innovative policy to support the commercial neuroscience ecosystem globally," shared Alison.
Alison has a PhD in Neuroscience and an MBA from McMaster University, she also holds a Masters in Neurokinetics from the University of Quebec at Montreal, and Bachelor of Kinesiology (honors) from Brock University.
The neurotechnology sector has seen important increases in investment over the last decade, however, there remains significant unmet need across the majority of CNS diseases and disorders. The Neurotechnology Industry Organization, established in 2006, is the first and only trade organization representing commercial neuroscience globally.
About NIO
Since 2006, over 120 neuroscience organizations have joined the Neurotechnology Industry Organization in our mission to accelerate neurotechnology research, development and commercialization, including neuroscience companies, brain research institutes, and patient advocacy groups across the spectrum of neurological disease, psychiatric illnesses and nervous system injuries. NIO's programs have the following goals: advocate the industry's position to regulators and elected officials; inform the media about industry's progress and contributions to quality of life; provide industry events and business development services to the industry; foster leadership positions that drive innovation forward.
Contact:
Alison Fenney
Executive Director, NIO
Alison@neurotechindustry.org
